News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Berkman Charles S
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 01/05/2023 |
4
| Berkman Charles S (See Remarks) has filed a Form 4 on OmniAb, Inc.|
Txns:
| Granted 46,864 shares
@ $0 |
|
| 12/30/2022 |
4
| Berkman Charles S (See Remarks) has filed a Form 4 on OmniAb, Inc.|
Txns:
| Paid exercise price by delivering 6,518 shares
@ $3.66, valued at
$23.9k
|
|
| 12/09/2022 |
4
| Berkman Charles S (See Remarks) has filed a Form 4 on OmniAb, Inc.|
Txns:
| Granted 175,477 options
@ $3.68, valued at
$645.8k
|
|
| 12/05/2022 |
4
| Berkman Charles S (See Remarks) has filed a Form 4 on OmniAb, Inc.|
Txns:
| Paid exercise price by delivering 10,580 shares
@ $3.35, valued at
$35.4k
|
|
| 11/03/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/03/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/03/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/03/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 09/30/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 06/14/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/16/2022 |
4
| Berkman Charles S (SVP, Gen. Counsel & Secretary) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Paid exercise price by delivering 368 shares
@ $123.68, valued at
$45.5k
Paid exercise price by delivering 633 shares
@ $123.68, valued at
$78.3k
Paid exercise price by delivering 577 shares
@ $123.68, valued at
$71.4k
|
|
| 01/28/2022 |
4
| Berkman Charles S (SVP, Gen. Counsel & Secretary) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Granted 2,401 shares
@ $0
Granted 3,836 shares
@ $0
Paid exercise price by delivering 830 shares
@ $113.68, valued at
$94.4k
Paid exercise price by delivering 1,326 shares
@ $113.68, valued at
$150.7k
|
|
| 02/18/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/27/2021 |
4
| Berkman Charles S (SVP, Gen. Counsel & Secretary) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Granted 1,335 shares
@ $0
Paid exercise price by delivering 509 shares
@ $156.1, valued at
$79.5k
Granted 2,401 shares
@ $0
Paid exercise price by delivering 830 shares
@ $156.01, valued at
$129.5k
|
|
| 07/01/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/05/2020 |
4
| Berkman Charles S (SVP, Gen. Counsel & Secretary) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Sold 11,146 shares
@ $118.5874, valued at
$1.3M
|
|
| 02/18/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/26/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/06/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/02/2019 |
4
| Berkman Charles S (SVP, Gen. Counsel & Secretary) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Acquired 182 shares
@ $97.0275, valued at
$17.7k
|
|
| 02/13/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/25/2019 |
4
| Berkman Charles S (SVP, Gen. Counsel & Secretary) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Granted 1,370 shares
@ $0
Granted 1,412 shares
@ $0 |
|
| 01/14/2019 |
4
| Berkman Charles S (SVP, Gen. Counsel & Secretary) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Exercised 244 options to buy
@ $21.92, valued at
$5.3k
Exercised 675 options to buy
@ $56.26, valued at
$38k
Exercised 1,931 options to buy
@ $74.42, valued at
$143.7k
|
|
| 12/17/2018 |
4
| Berkman Charles S (SVP, Gen. Counsel & Secretary) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Exercised 3,400 options to buy
@ $21.92, valued at
$74.5k
|
|
| 10/25/2018 |
4
| Berkman Charles S (SVP, Gen. Counsel & Secretary) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Exercised 1,212 options to buy
@ $21.92, valued at
$26.6k
Exercised 2,688 options to buy
@ $14.47, valued at
$38.9k
|
|
| 10/12/2018 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/18/2018 |
4
| Berkman Charles S (SVP, Gen. Counsel & Secretary) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Sold 2,813 shares
@ $250.6866, valued at
$705.2k
Exercised 2,813 options to buy
@ $100.38, valued at
$282.4k
|
|
| 09/05/2018 |
4
| Berkman Charles S (SVP, Gen. Counsel & Secretary) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Sold 19,417 shares
@ $254.9861, valued at
$5M
Exercised 7,077 options to buy
@ $56.26, valued at
$398.2k
Exercised 5,985 options to buy
@ $74.42, valued at
$445.4k
Exercised 5,886 options to buy
@ $85.79, valued at
$505k
Exercised 469 options to buy
@ $21.92, valued at
$10.3k
|
|
| 07/03/2018 |
4
| Berkman Charles S (SVP, Gen. Counsel & Secretary) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Acquired 180 shares
@ $117.8355, valued at
$21.2k
|
|
| 03/06/2018 |
4
| Berkman Charles S (SVP, Gen. Counsel & Secretary) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Granted 1,780 shares
@ $0
Granted 1,136 shares
@ $0
Paid exercise price by delivering 392 shares
@ $165.87, valued at
$65k
Granted 9,292 options to buy
@ $159.01, valued at
$1.5M
|
|
| 02/16/2018 |
4
| Berkman Charles S (SVP, Gen. Counsel & Secretary) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Paid exercise price by delivering 524 shares
@ $157.18, valued at
$82.4k
Paid exercise price by delivering 252 shares
@ $157.18, valued at
$39.6k
Paid exercise price by delivering 260 shares
@ $157.18, valued at
$40.9k
|
|
| 12/29/2017 |
4
| Berkman Charles S (VP, Gen. Counsel & Secretary) has filed a Form 4 on LIGAND PHARMACEUTICALS INC|
Txns:
| Granted 2,847 shares
@ $0
Paid exercise price by delivering 1,175 shares
@ $138.66, valued at
$162.9k
|
|
|
|
|